Glenmark Pharmaceuticals Limited

rs,

051 To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001 Scrip Name: GLENMARK ISIN: INE935A01035 Our Reference No. 21/26-

60%

Global pharmaceutical company Large Scale Focused Diversified ~US$2bn consolidated revenue1 >60% revenue contribution from Branded portfolio3 ~17,000 global employee base2 3 key therapeutic are

₹,

11 manufacturing sites2 globally across dosage forms 1. 2. 3. As of FY26 consolidated revenue in ₹, converted at the average exchange rate in 12M FY26 of 1US$ = ₹88.33 As of April 2026 As per FY27e co

₹88.33

As of FY26 consolidated revenue in ₹, converted at the average exchange rate in 12M FY26 of 1US$ = ₹88.33 As of April 2026 As per FY27e consolidated revenue; “Branded” include all branded markets (India, Em

29%

al Commercial Footprint India Emerging Markets Europe North America Revenue Contribution1 ~29% ~25% ~24% ~22% Key Markets Key Focus Areas2 Russia / CIS, LATAM, MEA, APAC WEU, CEE USA,

25%

mercial Footprint India Emerging Markets Europe North America Revenue Contribution1 ~29% ~25% ~24% ~22% Key Markets Key Focus Areas2 Russia / CIS, LATAM, MEA, APAC WEU, CEE USA, Canada

24%

l Footprint India Emerging Markets Europe North America Revenue Contribution1 ~29% ~25% ~24% ~22% Key Markets Key Focus Areas2 Russia / CIS, LATAM, MEA, APAC WEU, CEE USA, Canada Resp

22%

print India Emerging Markets Europe North America Revenue Contribution1 ~29% ~25% ~24% ~22% Key Markets Key Focus Areas2 Russia / CIS, LATAM, MEA, APAC WEU, CEE USA, Canada Respirator

1.5x

y Devices, Injectables 11 India: Market-beating Performance Through Strong Brand-building Growth 1.5x above IPM over the last 3 years1 Sharp focus on core therapeutic areas2 % growth Apr-23 Jul-23

rs1

Market-beating Performance Through Strong Brand-building Growth 1.5x above IPM over the last 3 years1 Sharp focus on core therapeutic areas2 % growth Apr-23 Jul-23 Oct-23 Jan-24 Apr-24 Jul-24 Oc

2 %

Brand-building Growth 1.5x above IPM over the last 3 years1 Sharp focus on core therapeutic areas2 % growth Apr-23 Jul-23 Oct-23 Jan-24 Apr-24 Jul-24 Oct-24 Jan-25 Apr-25 Jul-25 Oct-25 Jan

₹1,000

Apr-25 Jul-25 Oct-25 Jan-26 IPM Glenmark Legacy of creating mega-brands4 11 brands with >₹1,000mn 16 brands with >₹500mn 11 brands in IPM Top-300 1. 2. 3. 4. 5. As per IQVIA dataset from

Focused capital allocation

1

Current Ratings

1

Focused capital allocation

• • • ISB 2301 IND filing to be completed by end-CY26 Two additional discovery programs in Oncology to progress forward Targeting 1 IND filing every year • Average annual investment to remain ~US$70 million Creating Long-term Shareholder Value Anurag Mantri Executive Director & Global Chief Financial Officer Delivering on Strategic & Financial Commitments Criteria Investor Day 2022 Guidance Achievement Revenue 10-12% growth over next 3-4 years ~12% CAGR between FY22-FY26 Branded Business Contribution ~2/3rd of consolidated revenue to be contributed by branded markets On track >60% revenue from branded markets Innovation Portfolio Launch Commercial launch of 1 innovative asset Innovative Oncology: TEVIMBRA®, BRUKINSA® Specialty Dermatology: WINLEVI® EBITDA Margin 23% by FY27 21-22% guidance for FY27e ROCE 23% by FY27 >23% in FY27e On track post growth expansion investments IGI Funding Ensure IGI is self-funded ISB 2001 licensing deal with AbbVie Net Debt Zero net debt by FY26 Zero gross

Current Ratings

• • • S&P: BB+ (stable) Crisil: AA (positive) India Ratings: IND AA (positive) Peer Avg.1 Glenmark Peer Avg.1 Glenmark Balance sheet fortification → stronger return profile and financial flexibility 1. 2. 3. Based on consensus estimates for FY27 of select listed pharmaceutical companies with a similar business model and geographical presence FY27e ROCE = EBIT / Capital Employed; Capital Employed = Average debt + Average shareholder’s equity FY27e ROE = Net profit / Average shareholder’s equity 36 Well Defined Path to Deliver Substantial Shareholder Value Driver Medium-term Outlook Growth • Broad-based growth with greater contribution from branded markets • Revenue Growth: 13-15% CAGR Profitability • Growth initiatives with shorter payback periods and superior returns • Target ~1% margin improvement in FY28 through operating leverage Investments • Working capital to be structurally below industry average • ROCE-gated selective CAPEX and M&A to support long-term growth Return Ratios • Co